San Diego, CA. (PRWEB) March 23, 2015
SIWA Regenerative Medicine Corporation announced today that Lewis Gruber, founder, CEO and inventor of SIWA’s injectable drug-based approach to clearing senescent cells for increasing healthspan, will join scientists from Charles River Laboratories at 2:45 p.m. on March 23, 2015 in San Diego at the Society of Toxicology Annual Meeting to discuss and present SIWA’s demonstration of successful use in naturally aged CD-1 mice of a monoclonal version of SIWA’s drug candidate. The results of the work performed by Charles River for SIWA include an increase in gastrocnemius muscle mass and reduction of a senescent cell mRNA marker to the level of young mouse controls. Senescent cells have been implicated in many of the diseases associated with aging from Alzheimer’s disease and atherosclerosis to rheumatoid arthritis and sarcopenia.
SIWA Regenerative Medicine Corporation was formed in 2006 to develop inventions that it believes can retard or reverse the aging process by promoting tissue and organ regeneration. SIWA believes these inventions also can be applied as therapies in lessening the impact of diseases associated with aging. Specifically, SIWA has developed processes for selectively identifying and removing cells that inhibit regeneration. Such removal obtains the recognized benefits in health and function associated with cellular regeneration.
Prior to founding SIWA, Mr. Gruber was a founder of a genomics company. While CEO of the company, it completed the largest initial public offering of a biotechnology company in 1997 and obtained collaborations totaling over $100 million. He also was a founder of a nanotechnology company. While CEO of that company, it won awards for World Economic Forum Technology Pioneer (2005), Red Herring Top 100 Innovator (2004), and Chicago Innovation (2004). Mr. Gruber is a Trustee of the Field Museum of Natural History, and a member of the Madison Council and the Visiting Committee of the Oriental Institute at the University of Chicago.